JUPITER, Fla. — October 30, 2025 — Leads & Copy — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in upcoming investor conferences, including the UBS Global Healthcare Conference, the Stifel 2025 Healthcare Conference, and the Southwest IDEAS 2025 Investor Conference.
Ligand management will host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging meetings should contact their UBS or Stifel representative.
Ligand is a biopharmaceutical company focused on clinical development of high-value medicines, providing financing and licensing technologies.
For Investors:Melanie Herman, investors@ligand.com, (858) 550-7761; For Media: Kellie Walsh, media@ligand.com, (914) 315-6072
Source: Ligand Pharmaceuticals
